Collgard Biopharmaceuticals Overview

  • Year Founded
  • 1996

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1M

Collgard Biopharmaceuticals General Information

Description

Developer of tissue therapeutics. The company develops unique therapeutic products that affect the turnover of collagen to prevent or treat scleroderma, solid tumors, restenosis and other fibrotic disorders.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 15 Gonen Street
  • Kiryat Matalon
  • Petach Tikva
  • Israel
Primary Industry
Pharmaceuticals
Vertical(s)
Corporate Office
  • 15 Gonen Street
  • Kiryat Matalon
  • Petach Tikva
  • Israel

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Collgard Biopharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 01-Mar-2011 $1M Completed Product Development
2. Early Stage VC Completed
1. Early Stage VC (Series A) $7M $7M Completed
To view Collgard Biopharmaceuticals’s complete valuation and funding history, request access »

Collgard Biopharmaceuticals Patents

Collgard Biopharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20080255165-A1 Having the (2''r,3''s)trans configuration and being essentially free of the (2''s,3''r)trans enantiomer and 3 position of piperidine ring substituted with hydroxy, acetoxy or lower alkoxy; disorders associated with fibrotic conditions or cell proliferation; side effect reduction Inactive 23-Feb-2005
AU-2006217453-A1 Pharmaceutical compositions of the isolated d- enantiomer of the quinazolinone derivative halofuginone Inactive 23-Feb-2005
CA-2600046-A1 Pharmaceutical compositions of the isolated d- enantiomer of the quinazolinone derivative halofuginone Inactive 23-Feb-2005
EP-1855684-A2 Pharmaceutical compositions of the isolated d- enantiomer of the quinazolinone derivative halofuginone Inactive 23-Feb-2005
EP-1855684-A4 Pharmaceutical compositions of the isolated d- enantiomer of the quinazolinone derivative halofuginone Inactive 23-Feb-2005 A61K31/517
To view Collgard Biopharmaceuticals’s complete patent history, request access »

Collgard Biopharmaceuticals Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Denali Ventures Venture Capital Minority
Medica Venture Partners Venture Capital Minority
To view Collgard Biopharmaceuticals’s complete investors history, request access »

Collgard Biopharmaceuticals FAQs

  • When was Collgard Biopharmaceuticals founded?

    Collgard Biopharmaceuticals was founded in 1996.

  • Where is Collgard Biopharmaceuticals headquartered?

    Collgard Biopharmaceuticals is headquartered in Petach Tikva, Israel.

  • What industry is Collgard Biopharmaceuticals in?

    Collgard Biopharmaceuticals’s primary industry is Pharmaceuticals.

  • Is Collgard Biopharmaceuticals a private or public company?

    Collgard Biopharmaceuticals is a Private company.

  • What is the current valuation of Collgard Biopharmaceuticals?

    The current valuation of Collgard Biopharmaceuticals is .

  • What is Collgard Biopharmaceuticals’s current revenue?

    The current revenue for Collgard Biopharmaceuticals is .

  • How much funding has Collgard Biopharmaceuticals raised over time?

    Collgard Biopharmaceuticals has raised $20M.

  • Who are Collgard Biopharmaceuticals’s investors?

    Denali Ventures and Medica Venture Partners have invested in Collgard Biopharmaceuticals.

  • When was Collgard Biopharmaceuticals acquired?

    Collgard Biopharmaceuticals was acquired on 01-Mar-2011.

  • Who acquired Collgard Biopharmaceuticals?

    Collgard Biopharmaceuticals was acquired by Akashi Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process